WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Technology Software Products Friday, January 19, 2018 
Add Press Release News | News Feeds Feeds | Email This News Email


This Morning's Technical Outlook on Biotech Stocks -- Moleculin Biotech, Vanda Pharma, Iovance Biotherapeutics, and Bellicum Pharma
Friday, January 12, 2018

NEW YORK, Jan. 12, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on MBRX, VNDA, IOVA, and BLCM which can be accessed for free by signing up to www.wallstequities.com/registration. Today's pre-market research on WallStEquities.com is dedicated to the Biotechnology space, which is a highly volatile and unpredictable sector due to the scientifically intensive operations of companies that reside in it. Markets served include Medical, Agricultural, Environmental, and Industrial. Under evaluation this morning are the following stocks: Moleculin Biotech Inc. (NASDAQ: MBRX), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), and Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Moleculin Biotech

Houston, Texas headquartered Moleculin Biotech Inc.'s shares jumped 4.99%, closing Thursday's trading session at $1.89. The stock recorded a trading volume of 179,623 shares. The Company's shares have advanced 6.77% in the last month. The stock is trading 5.74% above its 50-day moving average and 8.91% above its 200-day moving average. Additionally, shares of Moleculin Biotech, which focuses on the development of anti-cancer drug candidates, have a Relative Strength Index (RSI) of 57.18.

On December 20(th), 2017, research firm ROTH Capital initiated a 'Buy' rating on the Company's stock, with a target price of $8 per share.

On December 21(st), 2017, Moleculin Biotech announced that the Ethics Committee in Poland has approved the Company's Phase-I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia. A site initiation visit for the first treatment site was completed that week, and treatment of patients in Poland is now subject only to confirmation by the Polish National Office that all necessary forms have been properly filed. The Company expects the first patient to be enrolled in Q1 2018. Get the full research report on MBRX for free by clicking below at:

www.wallstequities.com/registration/?symbol=MBRX

Vanda Pharmaceuticals

On Thursday, shares in Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc. recorded a trading volume of 474,062 shares. The stock rose 2.14%, ending the day at $14.35. The Company's shares have advanced 3.61% in the past month and 2.50% over the past year. The stock is trading slightly above its 50-day moving average by 0.68%. Furthermore, shares of Vanda Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 47.41.

On January 07(th), 2018, Vanda Pharmaceuticals announced its 2018 financial guidance. The Company expects to achieve net product sales from both HETLIOZ(®) and Fanapt(®) of between $180 million and $200 million; HETLIOZ(®) net product sales of between $108 million and $118 million; and Fanapt® net product sales of between $72 million and $82 million. Non-GAAP operating expenses for this year, excluding cost of goods sold, are expected to be between $163 million and $173 million; and year-end 2018 cash is expected to be between $115 and $125 million. VNDA's complimentary research coverage is a few simple steps away at:

www.wallstequities.com/registration/?symbol=VNDA

Iovance Biotherapeutics

San Carlos, California headquartered Iovance Biotherapeutics Inc.'s stock finished the day 3.49% higher at $8.90 with a total trading volume of 413,115 shares. The Company's shares have advanced 0.56% in the last month, 19.46% in the previous three months, and 23.61% over the past year. The stock is trading above its 50-day and 200-day moving averages by 7.13% and 27.79%, respectively. Additionally, shares of Iovance Biotherapeutics, which focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells, have an RSI of 59.59. Register for your free research report on IOVA at:

www.wallstequities.com/registration/?symbol=IOVA

Bellicum Pharmaceuticals

Shares in Houston, Texas headquartered Bellicum Pharmaceuticals Inc. ended yesterday's session 0.34% higher at $8.90. The stock recorded a trading volume of 297,197 shares. The Company's shares are trading 5.25% below their 50-day moving average. Moreover, shares of Bellicum Pharma, which focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the US and internationally, have an RSI of 45.92. Wall St. Equities' downloadable research report on BLCM available at:

www.wallstequities.com/registration/?symbol=BLCM

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-biotech-stocks----moleculin-biotech-vanda-pharma-iovance-biotherapeutics-and-bellicum-pharma-300581878.html

SOURCE Wall St. Equities



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav qPCR and dPCR Instrumentation Markets, 2016-2024 - Global Strategic Business Report 2018: Increasing Incidence and Prevalence of Cancer: A Grim Reality Driving Demand for qPCR and dPCR | Jan 18, 2018
Nav Vodka Must "Grow Up" or Face Continued Global Struggles - Latest Research from just-drinks and the IWSR | Jan 18, 2018
Nav New Multi-year Partnership Sees Times Higher Education Continue to Draw on Elsevier's Scopus Data for its World University Rankings | Jan 18, 2018
Nav Epson Announces Next-Generation SureColor F2100 Printer for High-Performance Direct-to-Garment Printing | Jan 18, 2018
Nav CreditPoint Software, LLC and Creditsafe Announce Integrated Risk Management Partnership | Jan 18, 2018
Nav MMR's Bruce Olson to Speak at The Quirks Event | Jan 18, 2018
Nav A New Generation of Intuitive Vendor Management Systems Is Here | Jan 18, 2018
Nav Attunity to Report Fourth Quarter and Full Year 2017 Results on February 1, 2018 | Jan 18, 2018
Nav Riffyn Opens Boston Office to Meet Accelerating Demand for Digital Transformation in Biotech and Pharmaceutical R&D | Jan 18, 2018
Nav Frost & Sullivan Recognizes Bentley Systems as a Global Provider of Customer Value for Its Future-Ready Asset Performance Management Software Solutions | Jan 18, 2018
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News